This prospective , randomized , multicenter study is going to assess the hypothesis that in persistent or permanent AF patients ( score of CHADSVASc2 ) after PCI-eS , the combination therapy of oral anticoagulation ( warfarin ) and ticagrelor ( 90 mg/bid ) could reduce the risk of bleeding events .